References
- The Global Asthma Report 2014 [Internet]. [cited 2016 Oct 31]. Available from: http://www.globalasthmareport.org/burden/burden.php
- Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64(6):476–483.
- Carvajal-Urueña I, García-Marcos L, Busquets-Monge R, et al. Geographic variation in the prevalence of asthma symptoms in Spanish children and adolescents. International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3, Spain. Arch Bronconeumol. 2005;41(12):659–666.
- Plaza-Martín AM, Vennera MC, Galera J, et al. Prevalence and clinical profile of difficult-to-control severe asthma in children: results from pneumology and allergy hospital units in Spain. Allergol Immunopathol (Madr). 2014;42(6):510–517.
- Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–1372.
- Sánchez-Bahíllo M, García-Marcos L, Pérez-Fernández V, et al. Trends in asthma mortality in Spain from 1960 to 2005. Arch Bronconeumol. 2009;45(3):123–128.
- McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013;73(11):1197–1212.
- Licari A, Marseglia GL, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042.
- Xolair, INN-omalizumab - WC500057298.pdf [Internet]. [cited 2014 Jun 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
- Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
- Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
- Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216.
- Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015.
- Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient? Drugs. 2014;74(5):521–533.
- Bush A, Pavord ID. Omalizumab: NICE to USE you, to LOSE you NICE. Thorax. 2013;68(1):7–8.
- Chipps BE, Figliomeni M, Spector S. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proc. 2012;33(5):377–385.
- Di Domenico M, Bisogno A, Polverino M, et al. Xolair in asthma therapy: an overview. Inflamm Allergy Drug Targets. 2011;10(1):2–12.
- Luu M, Bardou M, Bonniaud P, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2016;12(12):1503–1511.
- Bergrath E, Hwa Ong S, Bousquet J, et al. Systematic review of observational studies and RCTs of omalizumab in severe persistent allergic asthma and meta-analysis feasibility assessment. Value Health. 2014;17(7):A589.
- Robinson PD, Van Asperen P. Newer treatments in the management of pediatric asthma. Paediatr Drugs. 2013;15(4):291–302.
- Bush A, Pedersen S, Hedlin G, et al. Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Eur Respir J. 2011;38(4):947–958.
- Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502.
- Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–556.
- Matin N, Tabatabaie O, Falsaperla R, et al. Efficacy and safety of omalizumab in paediatric age: an update of literature data. J Biol Regul Homeost Agents. 2016;30(2):579–584.
- Omalizumab treatment for adults and children with allergic asthma: a review of the clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 [cited 2017 Feb 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK280029/
- SIGN 50: A guideline developer’s handbook - SIGN grading system 1999 – 2012 [Internet]. [cited 2017 Feb 26]. Available from: http://www.sign.ac.uk/guidelines/fulltext/50/annexoldb.html#
- Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110(5):e55.
- Silkoff PE, Romero FA, Gupta N, et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113(4):e308–312.
- Kulus M, Hébert J, Garcia E, et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285–1293.
- Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–171.
- Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485.
- Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–1233.
- Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–859.
- Brodlie M, McKean MC, Moss S, et al. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–609.
- P23 Effect of omalizumab on oral corticosteroid requirements of young children with severe asthma; results of a UK survey – Kirk et al. 65 (Suppl 4): A86 – thorax [Internet]. [cited 2014 Jun 21]. Available from: http://thorax.bmj.com/content/65/Suppl_4/A86.1
- Rizk C, Ring A, Santucci S, et al. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities. Ann Allergy Asthma Immunol. 2012;109(3):222–223.
- P88 real-life experience of omalizumab in children with severe asthma – Koo et al. 68 (Suppl 3): A115 – thorax [Internet]. [cited 2014 Jun 26]. Available from: http://thorax.bmj.com/content/68/Suppl_3/A115.1.abstract?sid=398b20eb-d5e0-4eca-ae82-cfce6a522843
- Folqué MM, Machinena A, Piquer M, et al. Niños con asma grave tratados con omalizumab. Experiencia de 4 años [Internet]. [cited 2014 Jun 26]. Available from: http://www.seicap.es/documentos/archivos/seicap_2012_cadiz_comunicaciones_web.pdf
- Corzo JL, Requena G, Muñoz C, et al. Uso de omalizumab en niños con asma alérgica persistente mal controlada [Internet]. [cited 2014 Jun 26]. Available from: http://www.seicap.es/documentos/archivos/seicap_2012_cadiz_comunicaciones_web.pdf
- Odajima H, Ebisawa M, Nagakura T, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106–115.
- Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017 Mar;13(1):36–42.
- TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): guidance [Internet]. [cited 2014 Jun 25]. Available from: http://guidance.nice.org.uk/TA278/Guidance/pdf/English
- van Nooten F, Stern S, Braunstahl G-J, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–348.
- Levy AN, García ARJ, García-Agua NS, et al. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015 Mar;52(2):205-210. doi:10.3109/02770903.2014.941474. Epub 2014 Nov 24.
- Walker S, Burch J, McKenna C, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. Health Technol Assess. 2011;15(Suppl 1):13–21.
- De Cock E, Miravitlles M, González-Juanatey JR, et al. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. Pharm Econ Spanish Res Articles. 2007;4(3):97–107.
- WHO | WHO-CHOICE [Internet]. [cited 2014 Nov 6]. Available from: http://www.who.int/choice/en/
- Requena Quesada G, Corzo Higueras JL, Muñoz Román C, et al. Práctica habitual de tratamiento con omalizumab en población pediátrica. Estudio fármacoeconómico de costes sanitarios. J Investig Allergol Clin Immunol. 2013;23(Supplement 2):92–164.
- Stokes J. Anti-IgE treatment for disorders other than asthma. Front Med. 2017;4:152.
- Nopp A, Johansson SGO, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60.
- Busse WW, Trzaskoma B, Omachi TA, et al. Evaluating Xolair persistency of response after long-term therapy (XPORT). Am J Respir Crit Care Med. 2014;189:A6576.
- Matricardi PM, Bockelbrink A, Keil T, et al. Dynamic evolution of serum immunoglobulin E to airborne allergens throughout childhood: results from the Multi-Centre Allergy Study birth cohort. Clin Exp Allergy. 2009;39(10):1551–1557.
- Tripodi S, Frediani T, Lucarelli S, et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol. 2012;129(3):834–839.e8.
- Maetzel A. Cost-effectiveness analysis: out of touch with clinical reality? Arthritis Rheum. 2005;53(1):3–4.
- Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. PharmacoEconomics. 2006;24(11):1121–1131.
- Hoey R. Experts disagree over NICE’s approach for assessing drugs. Lancet. 2007;370(9588):643–644.
- Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115(5):e600–614.
- Papadopoulos NG, Arakawa H, Carlsen K-H, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012;67(8):976–997.
- Brazilian Society of Pediatrics, Brazilian Association of Allergy and Immunopathology, Brazilian Society of Pneumology and Tisiology, Brazilian Society of Family and Community Medicine, Borges W, Burns D, et al. Asthma in childhood: drug therapy. Rev Assoc Médica Bras 1992 2011;57(4):362–369.
- Turner SW, Friend AJ, Okpapi A. Asthma and other recurrent wheezing disorders in children (chronic). BMJ Clin Evid. 2012 Jan 18;2012.
- Hamasaki Y, Kohno Y, Ebisawa M, et al. Japanese guideline for childhood asthma 2014. Allergol Int. 2014;63(3):335–356.
- Plaza Moral V, Alonso Mostaza S, Alvarez Rodríguez C, et al. Spanish guideline on the management of asthma. J Investig Allergol Clin Immunol. 2016;26(Suppl1):1–92.
- (*NEW) 2017 GINA report: global strategy for asthma management and prevention [Internet]. Glob. Initiat. Asthma – GINA; [ cited 2017 Feb 27]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
- BTS/SIGN British guideline on the management of asthma | British Thoracic Society [Internet]. [cited 2016 Nov 10]. Available from: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/
- Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir. 2012;19(2):127–164.
- Institute for Clinical Systems Improvement. Diagnosis ANS management of Asthma.pdf [Internet]. [cited 2017 Feb 27]. Available from: https://www.icsi.org/_asset/rsjvnd/Asthma.pdf
- Department of Veterans Affairs. Department of Defense. VA/DoD clinical practice guideline for management of asthma in children and adults[Internet]. [cited 2017 Feb 27]. Available from: http://www.healthquality.va.gov/guidelines/CD/asthma/ast_2_sum.pdf
- University of Michigan. Guidelines for clinical care ambulatory. Asthma [Internet]. [cited 2017 Feb 27]. Available from: http://www.med.umich.edu/1info/FHP/practiceguides/asthma/asthmagdln.pdf
- Australian Asthma Handbook | management | children [Internet]. Aust. Asthma Handb. [cited 2017 Feb 27]. Available from: http://www.asthmahandbook.org.au/management/children
- Cisneros Serrano C, Melero Moreno C, Almonacid Sánchez C, et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–246.
- Navarro Merino M, Andrés Martín A, Asensio de la Cruz O, et al. Diagnosis and treatment guidelines for difficult-to-control asthma in children. An Pediatría 2003. 2009;71(6):548–567.
- Neffen H, Vidaurreta S, Balanzat A, et al. Poorly controlled asthma: diagnosis and therapeutics in children and adolescents. Medicina (Mex). 2012;72(5):403–413.
- Guía Española para el Manejo del Asma. Guía GEMA 4.2 [Internet]. [cited 2017 May 26]. Available from: http://www.gemasma.com/
- Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, et al. IgE-related chronic diseases and anti-IgE-based treatments. J Immunol Res. 2016;2016:8163803.